In the randomized, double-blind, phase 3 study, experts explored treatment with neoadjuvant pembrolizumab (Keytruda) plus chemotherapy, followed by adjuvant pembrolizumab, in patients aged 18 years ...

The following is a summary of "A phase 2 study of frontline pembrolizumab in follicular lymphoma," published in the October 2024 issue of Hematology by Ho et al. The tumor microenvironment (TME), ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more ...

The imaging agent Gleolan is only approved for glioma surgery, so the current trial could lead to a new indication. In this ...

Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab yields a significant improvement in overall survival ...

It is important to educate and bring awareness to childhood lymphoma, its symptoms, treatment options, and the need for ...

KEYTRUDA’s safety profile in this trial was found to be in line with previous studies, without any new safety concerns ...